title: HLA-A0201 positive pancreatic cell lines: new findings and discrepancies.
abstract: Pancreatic cancer is being pursued as an immunotherapy target using antigen-specific vaccine approaches activating CD8(+) CTL and CD4(+) T-helper cells. CD8(+) CTL exert their anti-tumor effects in an HLA-restricted manner and only tumor cells carrying a matched HLA class I sub-type are targets for antigen-specific CTL. In the process of characterizing CD8(+) T cell responses against pancreatic cancer, we screened a number of human pancreatic tumor cell lines for HLA-A0201 positive (HLA-A2(+)) cell lines to be used in the evaluation of CTL function. This analysis revealed some new findings and discrepancies in the literature on the HLA sub-type of some commonly used pancreatic cell lines. We found that Capan-1 cells, originally reported to be HLA-A0201(+), actually only express HLA-A010101 and HLA-A300101 and were targets for HLA-A0201-restricted CTL only after transduction with an HLA-A0201-expressing lentivirus. Panc-1 cells were found to be HLA-A0201 positive, in agreement with published reports, while CF-Pac-1 cells were found to express both HLA-A020101 and HLA-A030101. We also found a normal human pancreatic ductal epithelial cell line, HPDE, to be HLA-A0201 positive. Our findings were verified with two different sequence-based typing methods, antibody staining followed by flow cytometry analysis, and functional analysis using an HLA-A0201-restricted peptide-specific T cell response.
authors.affiliation: Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Kuichun
authors.initials: K
authors.lastname: Zhu
authors.forename: Gregory
authors.initials: G
authors.lastname: Lizee
authors.forename: Pedro
authors.initials: P
authors.lastname: Cano
authors.forename: Marcelo
authors.initials: M
authors.lastname: Fernando-Vina
authors.forename: Baoan
authors.initials: B
authors.lastname: Ji
authors.forename: James L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
authors.forename: Laszlo
authors.initials: L
authors.lastname: Radvanyi
authors.forename: David Z
authors.initials: DZ
authors.lastname: Chang
mesh_terms: D001483:Base Sequence; D045744:Cell Line, Tumor / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015234:HLA-A Antigens / Q000096:biosynthesis* / Q000235:genetics*; D015789:HLA-A2 Antigen; D006650:Histocompatibility Testing; D006801:Humans; D008969:Molecular Sequence Data; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000276:immunology; D016133:Polymerase Chain Reaction
chemical_list: D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen